GOV Stock Chart & Stats
€122.35
€3.40(2.37%)
At close: 4:00 PM EDT
€122.35
€3.40(2.37%)
Day’s Range― - ―
52-Week Range€113.35 - €304.00
Previous CloseN/A
Volume0.00
Average Volume (3M)66.00
Market Cap
€7.89B
Enterprise Value€10.98K
Total Cash (Recent Filing)€534.90M
Total Debt (Recent Filing)€948.40M
Price to Earnings (P/E)24.6
Beta0.28
Next Earnings
Oct 29, 2026EPS Estimate
1.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.36
Shares Outstanding69,354,200
10 Day Avg. Volume39
30 Day Avg. Volume66
Financial Highlights & Ratios
PEG Ratio-1.97
Price to Book (P/B)13.20
Price to Sales (P/S)7.38
P/FCF Ratio52.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€145.49Price Target Upside18.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)5.6
Revenue Forecast (FY)€2.84B
Bulls Say, Bears Say
Bulls Say
Recurring Consumable ModelThe disposable pod model creates recurring revenue as users replace devices on a regular schedule. This supports visibility, strengthens customer retention economics, and can compound revenue as the installed customer base expands, rather than relying only on one-time hardware sales.
Strong Growth And Margin ExpansionInsulet is combining rapid top-line growth with expanding operating margins, indicating scale and manufacturing productivity are improving earnings quality. Sustained margin leverage can provide greater capacity to fund product development, commercial expansion, and future growth initiatives.
International And Access ExpansionInternational momentum and broader U.S. coverage expand the addressable market for Omnipod and reduce access barriers for patients. These structural commercial improvements can support adoption and strengthen the platform’s competitive position across geographies over multiple quarters.
Bears Say
Type 2 Retention ExecutionWeak onboarding and early retention among type 2 customers can reduce the lifetime value of new users and limit the durability of customer-base growth. Management has corrective actions underway, but their effectiveness remains unproven and creates an execution overhang.
Uneven Free Cash Flow ConversionInsulet generates meaningful positive cash flow, but uneven conversion and an expected decline in free cash flow reduce the reliability of internally generated funding. Continued pressure from capital spending and device corrections could constrain flexibility for investment or shareholder returns.
Meaningful Debt And Earnings VolatilityMeaningful debt increases financial obligations, while volatile net margins indicate that costs below the gross-profit line have not been fully stable. Together, these factors can make earnings and financial flexibility more sensitive to execution and operating-cost changes.
Insulet News
GOV FAQ
What was Insulet’s price range in the past 12 months?
Insulet lowest stock price was €113.35 and its highest was €304.00 in the past 12 months.
What is Insulet’s market cap?
Insulet’s market cap is €7.89B.
When is Insulet’s upcoming earnings report date?
Insulet’s upcoming earnings report date is Oct 29, 2026 which is in 46 days.
How were Insulet’s earnings last quarter?
Insulet released its earnings results on Aug 05, 2026. The company reported €1.43 earnings per share for the quarter, beating the consensus estimate of €1.264 by €0.165.
Is Insulet overvalued?
According to Wall Street analysts Insulet’s price is currently Undervalued.
Does Insulet pay dividends?
Insulet does not currently pay dividends.
What is Insulet’s EPS estimate?
Insulet’s EPS estimate is 1.37.
How many shares outstanding does Insulet have?
Insulet has 69,354,200 shares outstanding.
What happened to Insulet’s price movement after its last earnings report?
Insulet reported an EPS of €1.43 in its last earnings report, beating expectations of €1.264. Following the earnings report the stock price went down -20%.
Which hedge fund is a major shareholder of Insulet?
Currently, no hedge funds are holding shares in DE:GOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insulet Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€145.49 (18.92% Upside)
€145.49 (18.92% Upside)
Blogger Sentiment
Bullish
DE:GOV Sentiment 64%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.77%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
GOV Company Deck
GOV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive operational and financial performance — strong revenue, significant margin expansion, robust EPS growth, international strength, product and clinical progress, and solid liquidity — while transparently acknowledging a meaningful, addressable execution issue in onboarding and retaining type 2 customers that led to a modest downward revision to U.S. revenue outlook and a reassessment of longer-term assumptions. Management presented concrete actions (expanded customer care, sales compensation changes, sampling refinements, Omnipod Discover and data platform investments) to remediate retention and utilization in the first 90 days and expressed confidence these will translate into improved outcomes over time.View all DE:GOV earnings summariesGOV Revenue Breakdown
70.89% U.S. Omnipod
27.85% International Omnipod
1.26% Drug Delivery
GOV Stock 12 Month Forecast
Average Price Target
€145.49
▲(18.92% Upside)
Technical Analysis
Abbott Laboratories
―
Dexcom
―
Medtronic
―
Tandem Diabetes Care
―
Beta Bionics, Inc.
―